GlassScriptPhysician profile
Mark T Dahl
NPI 1508862194
$3,992,829.12
in general payments reported to CMS, 2019-2025
7 companies · $420K in 2025
The $420K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601K · 2020: $561K · 2021: $821K · 2022: $689K · 2023: $459K · 2024: $442K · 2025: $420K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.2M · Consulting Fee: $56K · Travel and Lodging: $42K · Food and Beverage: $773 · Honoraria: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,221,650.18 |
| Consulting Fee | $56,240.00 |
| Travel and Lodging | $41,967.22 |
| Food and Beverage | $772.93 |
| Honoraria | $416.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,751,729.18 | 2019-2025 | Hoffmann, Axsos, Variax |
| Nuvasive Specialized Orthopedics, INC. | $124,656.65 | 2019-2023 | Precice Intramedullary Limb Lengthening System |
| Orthofix Medical, INC. | $81,594.88 | 2022-2025 | Truelok, Fitbone, 3 Degree |
| Globus Medical, INC. | $34,188.09 | 2024-2025 | Precice Intramedullary Limb Lengthening System, Precice® Intramedullary Limb Lengthening System |
| Curvafix, INC. | $416.67 | 2024 | Curvafix Im Implant |
| Medical Device Business Services, INC. | $215.74 | 2022 | |
| Smith+Nephew, INC. | $27.91 | 2023 | Spatial Frame, Smart Tsf |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.